RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胶质瘤是中枢神经系统最常见的原发性肿瘤。常规的胶质瘤治疗策略包括手术切除以及化疗和放疗。干扰素γ(IFN-γ)是一种可溶性二聚体细胞因子,参与胶质瘤的免疫逃逸。在本研究中,我们试图识别IFN-γ相关基因,以构建胶质瘤预后模型来指导其临床治疗。
从癌症基因组图谱(TCGA)和中国胶质瘤基因组图谱(CGGA)下载RNA序列和临床病理数据。使用单因素Cox分析和最小绝对收缩和选择算子(LASSO)回归算法,筛选IFN-γ相关预后基因以构建风险评分模型,并分析其与临床特征的相关性。绘制高精度列线图以预测预后,并使用校准曲线评估其性能。最后,分析免疫细胞浸润和免疫检查点分子表达,以探索与风险评分模型相关的肿瘤微环境特征。
从198个IFN-γ相关基因中筛选出4个基因,构建了具有良好预测性能的风险评分模型。与正常脑组织相比,胶质瘤组织中4个IFN-γ相关基因的表达显著升高(p < 0.001)。基于ROC分析,风险评分模型准确预测了胶质瘤患者在1年(AUC:癌症基因组图谱0.89,CGGA 0.59)、3年(AUC:TCGA 0.89,CGGA 0.68)和5年(AUC:TCGA 0.88,CGGA 0.70)的总生存率。Kaplan-Meier分析显示,高风险组的总生存率显著低于低风险组(p < 0.0001)。此外,高风险评分与野生型 IDH1、野生型 ATRX 和 1P/19Q 非共缺失相关。列线图基于风险评分以及年龄、性别、病理分级和 IDH 状态等多个临床病理因素预测胶质瘤患者的生存率。风险评分与浸润性免疫细胞包括 CD8 T 细胞、静息 CD4 记忆 T 细胞、调节性 T 细胞(Tregs)、M2 巨噬细胞、静息 NK 细胞、活化肥大细胞和中性粒细胞呈正相关(p < 0.05)。此外,风险评分与免疫检查点分子的表达密切相关,如 PD-1、PD-L1、CTLA-4、LAG-3、TIM-3、TIGIT、CD48、CD226 和 CD96。
我们的风险评分模型揭示了 IFN-γ 相关基因是预测胶质瘤总生存期的独立预后因素,其与免疫细胞浸润和免疫检查点分子表达密切相关。该模型将有助于预测胶质瘤患者的免疫治疗有效性和生存率。
Background: Glioma is the most common primary tumor of the central nervous system. The conventional glioma treatment strategies include surgical excision and chemo- and radiation-therapy. Interferon Gamma (IFN-γ) is a soluble dimer cytokine involved in immune escape of gliomas. In this study, we sought to identify IFN-γ-related genes to construct a glioma prognostic model to guide its clinical treatment.
Methods: RNA sequences and clinicopathological data were downloaded from The Cancer Genome Atlas (TCGA) and the China Glioma Genome Atlas (CGGA). Using univariate Cox analysis and the Least Absolute Shrinkage and Selection Operator (LASSO) regression algorithm, IFN-γ-related prognostic genes were selected to construct a risk scoring model, and analyze its correlation with the clinical features. A high-precision nomogram was drawn to predict prognosis, and its performance was evaluated using calibration curve.
Finally, immune cell infiltration and immune checkpoint molecule expression were analyzed to explore the tumor microenvironment characteristics associated with the risk scoring model. Results: Four out of 198 IFN-γ-related genes were selected to construct a risk score model with good predictive performance. The expression of four IFN-γ-related genes in glioma tissues was significantly increased compared to normal brain tissue ( p < 0.
001). Based on ROC analysis, the risk score model accurately predicted the overall survival rate of glioma patients at 1 year (AUC: The Cancer Genome Atlas 0. 89, CGGA 0. 59), 3 years (AUC: TCGA 0. 89, CGGA 0. 68), and 5 years (AUC: TCGA 0. 88, CGGA 0. 70). Kaplan-Meier analysis showed that the overall survival rate of the high-risk group was significantly lower than that of the low-risk group ( p < 0. 0001).
Moreover, high-risk scores were associated with wild-type IDH1 , wild-type ATRX , and 1P/19Q non-co-deletion. The nomogram predicted the survival rate of glioma patients based on the risk score and multiple clinicopathological factors such as age, sex, pathological grade, and IDH Status, among others. Risk score and infiltrating immune cells including CD8 T-cell, resting CD4 memory T-cell, regulatory T-cell (Tregs), M2 macrophages, resting NK cells, activated mast cells, and neutrophils were positively correlated ( p < 0. 05).
In addition, risk scores closely associated with expression of immune checkpoint molecules such as PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, CD48, CD226, and CD96. Conclusion: Our risk score model reveals that IFN-γ -associated genes are an independent prognostic factor for predicting overall survival in glioma, which is closely associated with immune cell infiltration and immune checkpoint molecule expression. This model will be helpful in predicting the effectiveness of immunotherapy and survival rate in patients with glioma.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。